DNLI Q4 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$130M

Net Income

-$115M

EPS (Diluted)

$-0.67

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$89M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$144M

Stockholders' Equity

$1.2B

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$130M	-$133M	+2.1%
Net Income	-$115M	-$119M	+4.0%